Coherus BioSciences
333 Twin Dolphin Dr, #600
Redwood City
CA
94065
United States
Tel: 800-794-5434
Website: https://www.coherus.com/
About Coherus BioSciences
We are committed to making high-value biosimilars affordable for everyone. It’s an unconventional approach to business that defines who we are and what we do.
At Coherus, we hold ourselves to a higher standard. We don’t break the rules—we write our own.
In early 2021, we expanded our mission into immuno-oncology with a collaboration with Shanghai Junshi Biosciences for the development and commercialization of toripalimab, Junshi Biosciences’ novel anti-PD-1 antibody, in the United States and Canada.
We are embarking on a new phase in our evolution, focused on expanding patient access to important, cost-effective medicines and delivering significant savings to the U.S. healthcare system. Join us, as we seek to break down barriers and make a difference in patients’ lives.
Stock Symbol: CHRS
Stock Exchange: NASDAQ
195 articles with Coherus BioSciences
-
Coherus Highlights Anticipated New Product Launches and Immuno-oncology Growth Strategy at Analyst Day Event
3/29/2022
Coherus BioSciences, Inc., beginning at 9:30 a.m. Eastern Daylight Time , is hosting a meeting with analysts and investors to present the Company’s corporate strategy to build a leading innovative immuno-oncology franchise funded with cash generated through net sales of its diversified portfolio of FDA-approved therapeutics.
-
Coherus BioSciences to Highlight New Product Pipeline, Cancer Immunotherapy Development Plans at March 29, 2022 Analyst Day Event
3/22/2022
Coherus BioSciences, Inc. today announced that Coherus plans to host an Analyst Day on March 29, 2022 at 9:30 a.m. ET in New York City.
-
Biopharma and life sciences companies continue to strengthen their executive teams and boards with this week’s Movers & Shakers.
-
Junshi Biosciences and Coherus Announce Presentation of Positive Results from CHOICE-01
3/15/2022
Shanghai Junshi Biosciences Co., and Coherus Biosciences today announced the presentation of positive results and biomarker analyses from the pivotal study “CHOICE-01” (clinicaltrials.gov identifier# NCT03856411).
-
A checkpoint inhibitor under development by China’s Junshi Biosciences and Coherus BioSciences hit the mark in a Phase III lung cancer study.
-
Coherus BioSciences Appoints Rosh Dias, MD, MRCP, Chief Medical Officer
3/15/2022
Coherus BioSciences, Inc. announced Rosh Dias, MD, MRCP, has been appointed Chief Medical Officer.
-
Junshi Biosciences and Coherus Announce Positive Results from Phase 3 Esophageal Cancer Study of Toripalimab Published in Cancer Cell
3/4/2022
Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. today announced the online publication in Cancer Cell of Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): a multi-center randomized phase 3 trial.
-
Coherus Management to Present at Upcoming Investor Conferences in March 2022
3/4/2022
Coherus BioSciences, Inc., announced that senior management will present at the following investor conferences in March.
-
Coherus and Junshi Biosciences Announce Positive Results from Phase 3 Esophageal Cancer Study of Toripalimab Published in Cancer Cell
3/4/2022
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) and Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) today announced the online publication in Cancer Cell of Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): a multi-center randomized phase 3 trial.
-
BioSpace Movers & Shakers, Feb. 18
2/18/2022
Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers. -
Coherus BioSciences Reports Fourth Quarter and Full Year 2021 Results
2/17/2022
Coherus BioSciences, Inc., reported financial results for the quarter and full year ended December 31, 2021 and highlighted recent achievement of important milestones toward the Company’s key strategic initiatives:
-
Coherus Names Paul Reider Chief Commercial Officer
2/15/2022
Coherus BioSciences, Inc. (Nasdaq: “CHRS”, “the Company”, “Coherus”) today announced Paul Reider has been named Chief Commercial Officer.
-
Coherus BioSciences Announces New Employment Inducement Grants - Feb 14, 2022
2/14/2022
Coherus BioSciences, Inc., announced that effective Feb. 9, 2022, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 236,500 shares of the common stock of the Company to newly hired employees with a per share exercise price of $12.44, the closing trading price on the grant date.
-
Coherus BioSciences to Report Fourth Quarter and Full Year 2021 Financial Results on February 17th, 2022
2/11/2022
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its fourth quarter and full year 2021 financial results will be released after market close on Thursday, February 17, 2022.
-
BioSpace Movers & Shakers, Feb. 11
2/11/2022
Well into the new year, biopharma and life sciences companies bolster their executive leadership teams and boards with these Movers & Shakers. -
Coherus BioSciences Appoints Health Care Payer Expert Lee N. Newcomer, M.D., to Board of Directors
2/7/2022
Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS) today announced the appointment of board-certified oncologist and seasoned healthcare executive Lee N. Newcomer, M.D., to its Board of Directors effective February 2, 2022.
-
Coherus and Junshi Biosciences Expand Immuno-Oncology Collaboration to Include TIGIT-Targeted Antibody
1/10/2022
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) and Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) today announced that Coherus has initiated the process to exercise its option to license JS006, Junshi Biosciences’ TIGIT-targeted antibody, in the United States and Canada, expanding the companies’ 2021 immuno-oncology collaboration agreement.
-
Coherus BioSciences Secures Credit Financing with Pharmakon Advisors
1/7/2022
Coherus BioSciences, Inc. (Coherus or the Company) (Nasdaq: CHRS) today announced that it has entered into a loan agreement with investment funds managed by Pharmakon Advisors, LP.
-
Coherus BioSciences Management to Present at the 40th Annual J.P. Morgan Healthcare Conference
1/4/2022
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the virtual 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 9 a.m. EST / 6 a.m. PST.
-
Janssen Pharmaceutical says goodbye to San Francisco’s Theravance Biopharma after a disappointing performance from a drug the two companies were developing together.